[IMAGES BELOW] Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after >18 months of treatment“Eye bulging” metastatic breast cancer patient had failed 8 prior regimens, including antibody-drug conjugate (ADC) therapyPatient remains on BriaCell’s Phase 2 study with 29 treatment cycles completed PHILADELPHIA and VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or t ...